S&CO Inc. Buys 2,876 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

S&CO Inc. raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 128.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,121 shares of the medical equipment provider’s stock after acquiring an additional 2,876 shares during the period. S&CO Inc.’s holdings in Intuitive Surgical were worth $2,536,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ISRG. Geode Capital Management LLC grew its position in Intuitive Surgical by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider’s stock worth $4,039,200,000 after buying an additional 243,802 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Intuitive Surgical by 7.7% during the 4th quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider’s stock worth $2,165,184,000 after purchasing an additional 295,025 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Intuitive Surgical by 15.8% during the 4th quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider’s stock worth $1,889,126,000 after purchasing an additional 494,496 shares in the last quarter. Capital Research Global Investors increased its position in shares of Intuitive Surgical by 25.5% during the fourth quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider’s stock valued at $1,764,904,000 after purchasing an additional 687,906 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Intuitive Surgical by 54,010.7% in the first quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider’s stock valued at $14,999,630,000 after purchasing an additional 3,022,979 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In related news, SVP Mark Brosius sold 216 shares of the business’s stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 4,500 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president directly owned 353 shares of the company’s stock, valued at $173,845.44. The trade was a 92.73% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,610 shares of company stock worth $3,858,340. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Down 0.4%

Shares of ISRG opened at $493.95 on Tuesday. The stock’s fifty day simple moving average is $528.51 and its 200-day simple moving average is $534.63. The firm has a market capitalization of $177.07 billion, a PE ratio of 68.89, a price-to-earnings-growth ratio of 5.20 and a beta of 1.64. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. Intuitive Surgical’s revenue for the quarter was up 21.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.78 earnings per share. Analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Erste Group Bank reiterated a “hold” rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a “hold” rating to a “sell” rating and decreased their price objective for the company from $515.00 to $440.00 in a report on Monday, June 9th. Piper Sandler restated an “overweight” rating and set a $595.00 target price (up previously from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Wells Fargo & Company increased their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 23rd. Finally, UBS Group boosted their target price on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $592.05.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.